IRF5 and lung cancer: Furthermore, the mRNA expression of distinctive M2 markers (Arg1, IRF4) was increased, in metastatic lymph node tissues, whereas the expression of M1 markers (IRF5, TNF-a, iNOS) was restricted in early stage lung cancer samples (Fig. 2G), indicating T cell immunity suppression at a more advanced disease stage.